Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndrome”

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07752121
What this trial is testing

First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Who this might be right for
Myelodysplastic Neoplasms
Bristol-Myers Squibb 190
Not applicableStudy completedNCT00789256
What this trial is testing

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndromes
Dartmouth-Hitchcock Medical Center 26
Large-scale testing (Phase 3)Ended earlyNCT00695396
What this trial is testing

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 25
Testing effectiveness (Phase 2)Study completedNCT01444742
What this trial is testing

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
LeukemiaMyeloproliferative Diseases
M.D. Anderson Cancer Center 81
Testing effectiveness (Phase 2)Study completedNCT01995578
What this trial is testing

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Who this might be right for
Myelodysplastic Syndromes (MDS)Acute Myelogenous Leukemia (AML)
Memorial Sloan Kettering Cancer Center 32
Large-scale testing (Phase 3)Looking for participantsNCT06499285
What this trial is testing

Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Who this might be right for
Myelodysplastic Syndromes
Takeda 225
Testing effectiveness (Phase 2)Ended earlyNCT00495547
What this trial is testing

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
PETHEMA Foundation 16
Testing effectiveness (Phase 2)WithdrawnNCT01302106
What this trial is testing

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Testing effectiveness (Phase 2)Ended earlyNCT02599649
What this trial is testing

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT00382590
What this trial is testing

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT00451997
What this trial is testing

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Who this might be right for
Leukemia, MyeloidMyelodysplastic Syndromes
M.D. Anderson Cancer Center 10
Early research (Phase 1)Study completedNCT02038777
What this trial is testing

PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Pfizer 48
Post-approval studies (Phase 4)Study completedNCT00117507
What this trial is testing

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Who this might be right for
Myelodysplastic SyndromesIron Overload
Novartis Pharmaceuticals 24
Testing effectiveness (Phase 2)Study completedNCT00619099
What this trial is testing

Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome
Eisai Inc. 67
Testing effectiveness (Phase 2)Study completedNCT00068276
What this trial is testing

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Wake Forest University Health Sciences
Testing effectiveness (Phase 2)Looking for participantsNCT05384691
What this trial is testing

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Who this might be right for
Myelodysplastic SyndromesAnemia
University of Leipzig 213
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Large-scale testing (Phase 3)Study completedNCT01566695
What this trial is testing

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Celgene 216
Testing effectiveness (Phase 2)Study completedNCT01718379
What this trial is testing

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 132
Testing effectiveness (Phase 2)Ended earlyNCT04623996
What this trial is testing

TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Who this might be right for
Anemia in Myelodysplastic Syndromes
Sumitomo Pharma America, Inc. 2
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation